Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study

Health and Quality of Life Outcomes

Research

Evert Sanders¹  Sten Fredrikson²  Pierette Seeldrayers³  Magnus Andersson⁴  Peter J Jongen⁵  Joachim Speck⁶  Dirk Lehnick⁷ 

[1] Amphia Hospital, Breda, the Netherlands;Division of Neurology Huddinge, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden;Hospital Civil de Charleroi, Charleroi, Belgium;Karolinska Universitetssjukhuset i Solna, Solna, Sweden;MS4 Research Institute, Ubbergseweg 34, 6522, KJ Nijmegen, the Netherlands;Nuvisan GmbH, Neu-Ulm, Germany;STATPROC, Hohentengen am Hochrhein, Germany;

关键词: Expand Disability Status Scale;    Glatiramer Acetate;    Disease Modify Drug;    Relapse Remit Multiple Sclerosis;    Fatigue Impact Scale;   

DOI  :  10.1186/1477-7525-8-133

 received in 2010-08-19, accepted in 2010-11-15,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundGlatiramer acetate (GA) and interferon-beta (INFb) are first-line disease modifying drugs for relapsing remitting multiple sclerosis (RRMS). Treatment with INFb is associated with a significant increase in health-related quality of life (HR-QoL) in the first 12 months. It is not known whether HR-QoL increases during treatment with GA.Methods197 RRMS patients, 106 without and 91 with prior immunomodulation/immunosuppression, were studied for HR-QoL (Leeds Multiple Sclerosis-QoL [LMS-QoL] scale, score range 0 - 32), fatigue (Fatigue Impact Scale [FIS]) and depressed mood (Beck Depression Inventory-Short Form [BDI-SF]) at baseline and 6 and 12 months after start of GA treatment.ResultsAt 6 and 12 months mean LMS-QoL scores were significantly increased in the treatment-naive patient group (p < 0.001), not in the pre-treated group. At month 12 43% of treatment-naïve patients had improved HR-QoL (increase LMS-QoL score 3 or more points) (p < 0.001). Likewise, mean FIS scores were decreased at months 6 and 12 in the treatment-naïve group (p < 0.01), not in the pre-treated group. In both groups mean BDI-SF scores did not change. No demographic or clinical baseline factor was predictive of HR-QoL increase. HR-QoL changes were zero to negative for patients who had discontinued GA before month 12 (28.4% of patients).ConclusionsIn RRMS patients without prior immunomodulation/immunosuppression treatment with GA was associated with an increase in HR-QoL in the first 6 months, that was sustained at 12 months. In 4 out of 10 patients HR-QoL improved. Increase in HR-QoL was associated with decrease in fatigue.

【 授权许可】

CC BY   
© Jongen et al; licensee BioMed Central Ltd. 2010